Description
Phonyx Peptides TB-500 10 mg Research Peptide
Phonyx Peptides TB-500 10 mg is a single-compound research peptide vial containing a stated total of 10 mg of TB-500. TB-500 is a synthetic peptide based on the active region of thymosin beta-4. The common fragment sequence is Ac-LKKTETQ. The vial is lyophilized powder, labeled ≥99% purity, with lot number, expiry date and Research Use Only on the label.
The 10 mg figure is the total content of the Phonyx research format. It is not a dose and must not be read as a protocol.
What is TB-500?
TB-500 is studied as a thymosin beta-4–related fragment. Research interest sits on actin binding, cytoskeletal availability, cell migration, angiogenesis and tissue-repair signalling. Experimental models have looked at muscle, tendon, ligament, skin, cardiovascular and neural repair pathways.
It is not the same article as full-length thymosin beta-4. Topical wound studies of full-length Tβ4 do not transfer to this fragment, this route or this vial.
What research shows
Preclinical work in the thymosin beta-4 field reports higher keratinocyte migration, collagen deposition, angiogenesis, re-epithelialization and wound contraction in cell and animal models. One rat wound model reported increased re-epithelialization after full-length Tβ4 versus saline. In vitro work has reported about a 2–3× increase in keratinocyte migration under selected conditions. Those results belong to the Tβ4 research field. They are not a human efficacy claim for TB-500.
Phase 2 programmes of topical full-length Tβ4 in venous ulcers and pressure ulcers reported acceptable tolerability and a healing signal at 0.03% in one venous-ulcer study. That concentration, molecule and route are not TB-500 and cannot be converted into an injectable schedule.
There is no completed, peer-reviewed human efficacy trial showing that TB-500 speeds sports-injury recovery, raises athletic performance or provides a validated systemic repair protocol. A human half-life for the fragment is not established in completed peer-reviewed publications. Systemic safety, immunogenicity and dose-response remain incompletely characterized.
Specifications
Brand: Phonyx Peptides
Product: TB-500
Relation: Synthetic fragment of thymosin beta-4
Sequence: Ac-LKKTETQ
Total labeled content: 10 mg
Form: Lyophilized powder
Purity: ≥99%
Primary research domain: Actin binding and cell migration
Storage before reconstitution: Cool, dry and protected from light
Designation: Research Use Only
Storage and handling
Keep the unopened vial cool, dry and protected from light. Do not remove the label. Lot and expiry are the traceability record. Handle only under a laboratory SOP. Evidence from an authorized or clinical-grade Tβ4 product does not validate a different research material.
Research Use Only. Not for human consumption, self-administration, diagnosis, treatment, cure or prevention of any disease.